Reid Hoffman Bets on AI and Ultrasound: A Non-Invasive Brain Tech Revolution

By futureTEKnow | Editorial Team

Tech billionaire Reid Hoffman—best known as LinkedIn’s co-founder—is making headlines again, this time with a high-stakes bet on the future of brain health. Hoffman recently led a $12 million funding round for Sanmai Technologies, a stealth-mode startup merging artificial intelligence and ultrasound technology to tackle mental health and cognitive wellness.

The New Frontier: AI Meets Ultrasound

Tech billionaire Reid Hoffman—best known as LinkedIn’s co-founder—is making headlines again, this time with a high-stakes bet on the future of brain health. Hoffman recently led a $12 million funding round for Sanmai Technologies, a stealth-mode startup merging artificial intelligence and ultrasound technology to tackle mental health and cognitive wellness.

The New Frontier: AI Meets Ultrasound

Sanmai’s approach stands out in a crowded brain-tech field. Instead of invasive implants or daily medications, the company is developing a sub-$500, non-invasive headset that uses low-intensity focused ultrasound to stimulate targeted brain regions. This method, backed by years of clinical research, aims to address anxiety, depression, and cognitive decline without the side effects or risks associated with traditional treatments.

What sets Sanmai apart is its integration of AI. The headset’s AI assistant not only guides users through personalized therapy but also tackles technical challenges like skull distortion, adapting the treatment to each individual’s unique brain anatomy. This level of personalization is rare in the mental health tech space and could significantly improve outcomes.

The Bigger Picture: A Consumer-First Approach

While other brain-tech ventures—like Elon Musk’s Neuralink—are focused on surgical implants, Sanmai is betting on a lower-risk, consumer-friendly model. Their device is designed for home use, putting advanced mental health tools directly in the hands of everyday people. The company is already running clinical trials for generalized anxiety disorder in Sunnyvale, and is in discussions with the FDA to further validate its approach.

Hoffman’s investment signals a broader trend: tech billionaires are increasingly interested in funding innovations that push the boundaries of brain science. With over 20 companies now vying for leadership in this emerging market, Sanmai’s blend of science, safety, and AI could give it a real shot at reshaping how we think about—and treat—mental health.

Why This Matters for the Tech Industry

For tech enthusiasts and investors, Sanmai’s story is a reminder of how rapidly the landscape is evolving. The combination of AI and ultrasound opens up new possibilities for non-invasive brain therapies, potentially making advanced mental health care more accessible and affordable. And with Hoffman’s backing, Sanmai has the momentum and credibility to make a real impact.

As the brain-tech race heats up, it’s worth watching how companies like Sanmai balance innovation with safety—and whether their consumer-first approach can truly revolutionize mental health care.

futureTEKnow covers technology, startups, and business news, highlighting trends and updates across AI, Immersive Tech, Space, and robotics.

futureTEKnow

Editorial Team

futureTEKnow is a leading source for Technology, Startups, and Business News, spotlighting the most innovative companies and breakthrough trends in emerging tech sectors like Artificial Intelligence (AI), immersive technologies (XR), robotics, and the space industry.

Trending Companies

Latest Articles

Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.

Read More >